MX379555B - Procedimiento para la preparacion de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo. - Google Patents

Procedimiento para la preparacion de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo.

Info

Publication number
MX379555B
MX379555B MX2018013336A MX2018013336A MX379555B MX 379555 B MX379555 B MX 379555B MX 2018013336 A MX2018013336 A MX 2018013336A MX 2018013336 A MX2018013336 A MX 2018013336A MX 379555 B MX379555 B MX 379555B
Authority
MX
Mexico
Prior art keywords
sup
hydroxyalkyl
phenyl
producing
triazole
Prior art date
Application number
MX2018013336A
Other languages
English (en)
Spanish (es)
Other versions
MX2018013336A (es
Inventor
Chantal Fürstner
Frank Süssmeier
Hans-Christian Militzer
Heiko Schirmer
Kersten Matthias Gericke
Marie- Pierre COLLIN-KRÖPELIN
Philipp Rubenbauer
Thomas Neubauer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2018013336A publication Critical patent/MX2018013336A/es
Publication of MX379555B publication Critical patent/MX379555B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2018013336A 2016-05-03 2017-05-02 Procedimiento para la preparacion de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo. MX379555B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP16168163 2016-05-03
EP16168172 2016-05-03
EP16168165 2016-05-03
EP16168169 2016-05-03
EP16168166 2016-05-03
EP17160086 2017-03-09
PCT/EP2017/060367 WO2017191104A1 (de) 2016-05-03 2017-05-02 Verfahren zur herstellung von 5-hydroxyalkyl-substituierten 1-phenyl-1,2,4-triazolderivativen

Publications (2)

Publication Number Publication Date
MX2018013336A MX2018013336A (es) 2019-05-09
MX379555B true MX379555B (es) 2025-03-11

Family

ID=58633014

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018013336A MX379555B (es) 2016-05-03 2017-05-02 Procedimiento para la preparacion de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo.
MX2020010365A MX391356B (es) 2016-05-03 2017-05-02 Procedimiento para la preparacion de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010365A MX391356B (es) 2016-05-03 2017-05-02 Procedimiento para la preparacion de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo

Country Status (18)

Country Link
US (2) US10703742B2 (enExample)
EP (1) EP3452467A1 (enExample)
JP (2) JP6921863B2 (enExample)
KR (1) KR20190003536A (enExample)
CN (2) CN109071500B (enExample)
AU (2) AU2017259872B2 (enExample)
BR (1) BR112018072528A2 (enExample)
CA (1) CA3022789A1 (enExample)
CL (1) CL2018003107A1 (enExample)
CO (1) CO2018011948A2 (enExample)
IL (1) IL262534B (enExample)
MX (2) MX379555B (enExample)
PE (1) PE20190202A1 (enExample)
RU (1) RU2742885C2 (enExample)
SG (1) SG11201809672YA (enExample)
TW (1) TWI755393B (enExample)
UY (1) UY37222A (enExample)
WO (1) WO2017191104A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
US10703742B2 (en) * 2016-05-03 2020-07-07 Bayer Pharma Aktiengesellschaft Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4-triazole derivatives
CN109071464A (zh) * 2016-05-03 2018-12-21 拜耳制药股份公司 氧代烷基取代的苯基三唑衍生物及其用途
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139968A2 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2341776A4 (en) * 2008-09-19 2012-05-30 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES
DE102010001064A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
JP5826773B2 (ja) * 2010-02-27 2015-12-02 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ビスアリール−結合アリールトリアゾロン及びその用途
PE20142453A1 (es) * 2012-05-08 2015-01-17 Bayer Pharma AG Proceso preparativo
UY36383A (es) * 2014-11-03 2016-06-01 Bayer Pharma AG Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
US10703742B2 (en) * 2016-05-03 2020-07-07 Bayer Pharma Aktiengesellschaft Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4-triazole derivatives
CN109071464A (zh) * 2016-05-03 2018-12-21 拜耳制药股份公司 氧代烷基取代的苯基三唑衍生物及其用途

Also Published As

Publication number Publication date
JP2021143193A (ja) 2021-09-24
UY37222A (es) 2017-11-30
WO2017191104A1 (de) 2017-11-09
RU2018142264A3 (enExample) 2020-08-19
SG11201809672YA (en) 2018-11-29
US20200299271A1 (en) 2020-09-24
CL2018003107A1 (es) 2019-02-22
CA3022789A1 (en) 2017-11-09
PE20190202A1 (es) 2019-02-05
TWI755393B (zh) 2022-02-21
RU2018142264A (ru) 2020-06-03
MX2018013336A (es) 2019-05-09
RU2742885C2 (ru) 2021-02-11
MX391356B (es) 2025-03-19
CN109071500A (zh) 2018-12-21
CO2018011948A2 (es) 2018-11-22
AU2017259872B2 (en) 2021-06-24
KR20190003536A (ko) 2019-01-09
JP2019514948A (ja) 2019-06-06
CN113105403A (zh) 2021-07-13
AU2017259872A1 (en) 2018-11-22
IL262534B (en) 2021-04-29
IL262534A (en) 2018-12-31
US20190144431A1 (en) 2019-05-16
EP3452467A1 (de) 2019-03-13
MX2020010365A (es) 2022-04-06
AU2021236502A1 (en) 2021-10-21
CN109071500B (zh) 2021-05-18
JP6921863B2 (ja) 2021-08-18
BR112018072528A2 (pt) 2019-03-26
TW201815782A (zh) 2018-05-01
US10703742B2 (en) 2020-07-07

Similar Documents

Publication Publication Date Title
MX2020010365A (es) Procedimiento para la preparacion de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo.
IL281196B (en) Process for the preparation of methyl 6-(4,2-dichlorophenyl)-5-[4-[(s3)-1-(3-fluoropropyl)pyrrolidine-3-yl]oxyphenyl]-9,8-dihydro-h7-benzo[ 7] Anolene-2-carboxylate
NZ595553A (en) VINYL INDAZOLYL COMPOUND; (E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol
IL259609A (en) Method for producing 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(4,2,1-triazol-1-yl)propan-2-ol
JO3062B1 (ar) R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
CL2014000384A1 (es) Compuestos fungicidas de 1-(2-(2-halo-4-(4-halogen-fenoxi)-fenil)-2-alcoxi-2-alquinil/alquenil-etil)-1h-(1,2,4) triazol sustituidos; proceso para preparar dichos compuestos; composiciones agroquímicas.
EA023517B1 (ru) Модуляторы глюкагонового рецептора
SI2740731T1 (sl) Kristalinične soli inhibitorja za janus kinazo (r)-3-(4-(7h-pirolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopen tilpropannitrila
CL2014000534A1 (es) Procesos para preparar {1-{1-[3-fluoro-2-(trifluorometil)isonicotinoil]piperidin-4-il}-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo y compuestos intermediarios, inhibidores de jak; y compuesto intermediario (3-fluoro-2-(trifluorometil)piridin-4-il)(1,4-dioxa-8-azaspiro[4,5]decan-8-il)metanona.
JP2008546753A5 (enExample)
MX2023009857A (es) Inhibidores de la glucogeno sintasa 1 (gys1) y metodos de uso de los mismos.
IL285675A (en) Crystalline form of 1-(1-oxo-2,1-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
EP3377480A4 (en) 4 - ((6- (2,4-DIFLUROPHENYL) -1,1-difluoro-2-hydroxy-3- (1H-1,2,4-triazol-1-YL) PROPYL) PYRIDINE-3-YL) OXY ) BENZONITRILE AND METHOD OF PREPARING THEREOF
NZ624636A (en) Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
MY184577A (en) Method for the preparation of triazole compounds
GB2450268B (en) Synthesis of 4-[1-(4-cyano phenyl)-1-(1,2,4-triazol-1-yl)methyl]benzonitrile and 4-[1-(1,2,4-triazol-1-yl)methyl]benzonitrile intermediate
MY198496A (en) Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4- triazole derivatives
SI3841101T1 (sl) Postopek priprave 2-((3R)-3- metilmorfolin-4-il)-4-(1-metil-1H-pirazol-5-il)-8-(1H-pirazol-5-il)-1,7 -naftiridina
WO2007013096A8 (en) Improved process for the preparation of 2r, 3s-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) butan-2-ol (voriconazole)
EP3233824A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
EP3233079A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
IL291569A (en) Process for the production of 5-(4-((2s,5s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1h-4,2,1-triazol-3-amine
IL314283A (en) Methods for preparing ethyl 3-bromo-1-(3-chloropyridin-2-yl)-5,4-dihydro-H1-pyrazole-5-carboxylate
HK40065506A (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
AR076372A1 (es) Derivados de etil-tiotriazol, composiciones farmaceuticas que los comprenden, intermediarios para su sintesis y su uso en el tratamiento de trastornos mediados por mglur5